Search the Newsreel

Rhythm Biosciences (ASX:RHY): ColoSTAT's Commercial Momentum Is Ramping Up Quickly In FY27!

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $160.00

Citizens JMP raised its price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) to $160.00 from $155.00, maintaining a "market outperform" rating and suggesting a 47.56% upside. The company reported strong Q3 revenue of $71.25 million, exceeding estimates, and beat EPS expectations. Analyst sentiment remains largely positive …

Rhythm Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RYTM) 2026-08-05

Rhythm Pharmaceuticals, Inc. published its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of -$0.73, beating estimates by $0.10, and revenue of $71.26M, a 46.91% year-over-year increase, exceeding expectations by $3.60M. This report was issued in conjunction with …

Citigroup Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating

RBC Capital has increased its price target for Rhythm Pharmaceuticals (RYTM) to $155 from $141, while reiterating an Outperform rating on the stock. This adjustment follows Rhythm Pharmaceuticals' Q2 2026 earnings call and other recent news, including promising data for its drug in brain …

Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call

Rhythm Pharmaceuticals reported strong Q2 2026 results with global net product sales of IMCIVREE at $71.3 million, a 19% sequential increase. The company highlighted a successful U.S. launch of IMCIVREE for acquired hypothalamic obesity, receiving over 400 start forms in 14 weeks. Promising preliminary …

RHYTHM PHARMACEUTICALS, INC. 2026: Revenue $71.26M, EPS ($0.73) — 10-Q Summary

RHYTHM PHARMACEUTICALS, INC. (RYTM) reported its 2026 results, showing revenue of $71.26 million, a 46.9% increase from the prior year. Despite the revenue growth, the company posted a net loss of $50.36 million and a diluted EPS of ($0.73). The growth was primarily driven …

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals, Inc. announced that its Chairman, President and Chief Executive Officer, David Meeker, M.D., and Chief Financial Officer, Hunter Smith, will participate in fireside chats at three upcoming investor conferences in August and September 2026. These presentations will be webcasted and available on …

Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) reported a Q2 loss of $0.73 per share, exceeding the Zacks Consensus Estimate of a $0.81 loss by 9.88%. The company also surpassed revenue estimates, posting $71.26 million against an expectation of $67.12 million. Despite outperforming earnings expectations in three of …

Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q2 Revenue $71.3M, vs. FactSet Est of $67.7M

Rhythm Pharmaceuticals, Inc. reported its Q2 2026 revenue at $71.3 million, surpassing the FactSet estimate of $67.7 million. The company's lead asset, IMCIVREE, is an MC4R agonist approved for treating hyperphagia and severe obesity in various genetic and acquired conditions. Rhythm Pharmaceuticals is also …

Rhythm Pharmaceuticals 2Q Rev $71.3M >RYTM

Rhythm Pharmaceuticals reported its second-quarter revenue of $71.3 million. This brief report provides a key financial update for the company.

Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.09, revenue of $71.26M beats by $3.6M

* Rhythm Pharmaceuticals press release [https://seekingalpha.com/pr/20605381-rhythm-pharmaceuticals-reports-second-quarter-2026-financial-results-and-business-update] (RYTM [https://seekingalpha.com/symbol/RYTM]): Q2 GAAP EPS of -$0.73 beats by $0.09. * Revenue of $71.26M (+46.9% Y/Y) beats by $3.6M. * Net product revenues from global sales of IMCIVREE were $71.3 million for the second quarter of 2026, as …

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals reported strong second-quarter 2026 financial results, with global IMCIVREE sales reaching $71.3 million, a 19% sequential increase. The company highlighted a successful U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), with over 400 patient start forms, and positive clinical data for …

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced positive preliminary data from its Phase 2 trial of RM-718, an investigational once-weekly MC4R agonist, for acquired hypothalamic obesity (HO). The study showed an 11.6% mean reduction in BMI from baseline at Week 16, consistent with previous treatments like setmelanotide and …

After FDA approval, Rhythm's IMCIVREE logs more than 400 U.S. start forms

Rhythm Pharmaceuticals announced strong Q2 2026 financial results, with net product revenue from global IMCIVREE sales reaching $71.3 million, a 19% sequential increase. The growth was largely driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), which generated over 400 patient …

iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Look at Strong Analyst Ratings and Significant Growth Potential

Rhythm Pharmaceuticals (RYTM) is gaining investor attention due to its promising drug pipeline for rare neuroendocrine diseases and strong analyst endorsements. Despite current unprofitability and a slight stock price dip, its significant revenue growth and high average target price suggest substantial growth potential. Investors …

Algorhythm Holdings (NASDAQ: RIME) Among EZRA, RITR, HYFM, as SemiCab Expands Globally

Algorhythm Holdings (NASDAQ: RIME) is experiencing significant growth with its SemiCab platform, expanding globally and accelerating revenue. The company secured new enterprise customers like Coca-Cola India and Onida Electronics, while strengthening financial standing with a $9.5 million capital infusion and a $12 million annualized …

Rhythm Pharmaceuticals in spotlight: earnings test for HO launch By Investing.com

Rhythm Pharmaceuticals (RYTM) is under investor scrutiny as it prepares to release its Q2 earnings, which will provide the first detailed look at revenue from its newly approved treatment for acquired hypothalamic obesity (HO). Analysts are bullish, expecting an 81-cent loss per share on …

iRhythm Technologies $45M Securities Class Action Settlement

iRhythm Technologies and its CEO have agreed to a $45 million securities class action settlement. Investors who purchased the company's common stock between July 25, 2022, and August 9, 2024, may be eligible to claim a cash payment. The lawsuit alleged false and misleading …

Rhythm Pharmaceuticals (RYTM) Stock Looks Above Fair Value But Sales Stay Strong

Rhythm Pharmaceuticals (RYTM) has seen substantial stock growth over the past five years, but its current valuation suggests it is now overvalued, trading at a P/S ratio of 31.3x compared to an industry average of 10.5x and a fair P/S of 19.8x. While strong …

(RYTM) Volatility Zones as Tactical Triggers

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is showing divergent sentiment across horizons, indicating choppy conditions. AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each with specific entry, target, and stop loss levels. …

Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Janus Henderson Group PLC

Rhythm Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) generated a total revenue of $194.77 million USD last year. The majority of this revenue, $189.76 million USD, came from its Therapeutics segment. The United States was the largest geographical contributor, accounting for $133.55 million USD of the revenue.

iRhythm Technologies Inc (IRTC) Institutional Confidence

The article provides an analysis of iRhythm Technologies Inc's (IRTC) institutional confidence, noting its current score of 10.00, which ranks 1st in its industry. It details that the institutional shareholding proportion is 107.08%, with a slight decrease quarter-over-quarter. The largest institutional shareholder is Steven …

Rhythm Pharmaceuticals Inc (RYTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Rhythm Pharmaceuticals Inc (RYTM), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It shows that RYTM's stock price is currently trading between resistance at $114.09 and support at $99.21, suggesting suitability …

RYTM|Rhythm Pharmaceuticals Inc|Price:105.800|Chg%:-0.730

Rhythm Pharmaceuticals Inc (RYTM) has strong fundamentals, high growth potential, and is considered fairly valued within the pharmaceuticals industry. Institutional ownership is high, and analysts largely rate it as a "Buy" with an expected upward trend in the medium term. The company specializes in …

Precision Trading with Irhythm Technologies Inc. (IRTC) Risk Zones

This article provides a detailed analysis of Irhythm Technologies Inc. (IRTC) with a focus on risk zones for precision trading. It highlights a potential negative sentiment shift, weak broader alignment, and an exceptional short setup with a 55.8:1 risk-reward ratio targeting a 16.0% downside. …

RIME|Algorhythm Holdings Inc|Price:0.418|Chg%:+0.016

Algorhythm Holdings Inc (RIME) is an AI technology and consumer electronics holding company, with its primary business unit, SemiCab, focusing on AI-enabled logistics software. Despite healthy fundamentals and significant growth potential, the stock has shown very weak market performance over the past month. Analysts …

Algorhythm Holdings, Inc. Revenue Breakdown – NASDAQ:RIME

Algorhythm Holdings, Inc. (NASDAQ: RIME) generated $4.39 million USD in revenue last year, primarily from its SemiCab segment. This segment contributed the entire $4.39 million, a significant increase from $297,000 USD in the previous year. India was the primary revenue source, accounting for all …

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (IRTC) breached their fiduciary duties to shareholders. The firm encourages long-term iRhythm shareholders to contact them to discuss potential legal rights and options, including corporate …

iRhythm Holdings (IRTC) Could Be 34% Undervalued Following Its Recent Rebound

Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) on behalf of investors who purchased securities before January 11, 2022, and still hold them. The investigation aims to determine if iRhythm and its officers engaged in corporate wrongdoing. Shareholders …

Law firm investigates iRhythm officers over alleged stock price inflation via product misrepresentation

Kuehn Law, PLLC is investigating officers and directors of iRhythm Technologies for allegedly breaching fiduciary duties by misrepresenting their Zio AT monitor. The firm claims insiders falsely promoted the product's market potential, leading to artificially inflated stock prices. Investors who purchased shares before November …

Could Anticipated Q2 Earnings Beat Amid Weaker Profitability Reframe Rhythm Pharmaceuticals’ Growth Story (RYTM)?

In early August 2026, Rhythm Pharmaceuticals is scheduled to report quarterly results that analysts expect will show higher revenue but a year-over-year earnings decline, with many anticipating a potential earnings beat versus consensus estimates. This combination of rising sales and the prospect of outperforming …